Cancer is a serious and highly prevalent disorder that is triggered by a complex interplay of genetic factors. Drugs designed to act against individual molecular targets can\'t usually combat the multigenic disorder disease.[@b1],[@b2] Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems than the single drug. Drug-combination therapy has showed greater cell growth inhibition and population than either agent alone in cancers, which has been reported in many researches.[@b3],[@b4] Compared to the single drug therapy, multidrug therapy is less prone to drug resistance and risk,[@b2] and has less toxicity in small combining doses,[@b5] as well as a higher therapeutic effect.[@b6]--[@b8] It has become gradually the standard of care in cancer therapeutic areas.[@b3],[@b9] Generally, combinatorial drug effects could be classified into three types: additive, synergism, and antagonism: (i) When the effect of the drug combination is equal to that of the sum of the effects of the individual components, it is defined as additive; (ii) Synergistic action refers to the drug combinatory effect exceeding the additive effect of two individual components; (iii) Antagonism action refers to a reduced combinatory effect when compared with the effect of the most effective individual substance.[@b10] It remains a challenge to predict drug combinatory effects from two single drugs\' effect. Our current understanding of the drug interaction mechanics in multidrug therapy is more or less drug targeted-based.[@b1],[@b11] During the drug discovery process, predicting the drug combination effect *in vitro* heavily relies on the experiment. However, testing all possible combinations *in vitro* in cancer is not feasible due to the large combinatorial search space. Computational prediction may assist in identifying potential drug combination effects at the molecular level, such as an integrating method by molecular and pharmacological data,[@b4] a machine learning-based prediction of drug--drug interactions (DDIs) by integrating drug phenotypic, therapeutic, chemical, and genomic properties,[@b12] and large-scale pharmacogenomic screens of cancer cell lines.[@b13] These methods are promising strategies to predict unknown DDIs. However, these methods can\'t solve the key problem: how to detect and compare the dose response between the single and the combination drugs. The drug dose eventually needs to balance the benefit and risk from its efficacy and toxicity. On the other hand, some other methods emerged which were based on pathways of gene sets. These methods advanced our understanding about the drug responsive cellular processes.[@b14],[@b15] However, because of the potential knowledge bias of existing pathway databases, some critical genes may well not have been annotated for their functions and associated pathways. Hence, their roles in DDIs will be missed in these pathway-based approaches. Therefore, we hypothesize that drug responsive gene expression data are the most powerful and unbiased approach in predicting DDIs. In our study, we designed a new score schema to predict the drugs combination effect based on gene expression and their dose--responsive curve in cancer cell lines.

In 2006, Gustavo Stolovitzky and Andrea Califano founded the Dialogue on Reverse Engineering Assessment and Methods (DREAM) project. DREAM\'s purpose was to provide a reliable and reproducible platform to compare a large number of computational biology methods based on golden standard data. The inspiration for the DREAM project came from the success of the Critical Assessment of Structure Prediction (CASP) competition.[@b16] During the CASP competition, contestants were challenged to predict the final structure of a protein when given the amino acid sequence.[@b17] DREAM7-4 subchallenge 2 problem (DREAM7-4-2) asked the participating teams to predict the interactive activity of pairs of compounds in the OCI-LY3, a diffuse large B-cell lymphoma (DLBCL) cell line.[@b18],[@b19] **Figure** [1](#fig01){ref-type="fig"} describes the task overview. All contestants were given the gene expression data after separating treatments with 14 individual drugs at time intervals of 6, 12, and 24 hours in triplicate. The cells were also treated with dimethyl sulfoxide (DMSO) as controls. Dose--response curves of 9 out of 14 single drugs at 24 hours were also given. Using these curves, IC~20~ (20% inhibitory concentration) values were determined. Each contestant team was asked to predict pairwise drug interactions ordered from the most synergistic to the most antagonistic.[@b19]

![Overview of DREAM7-4 task. OCI-LY3 cell lines are treated with 14 different drugs at two different drug concentrations (IC~20~ at 24 and 48 hours, where IC~20~ is defined as concentration of drug needed to kill 20% of cells). The gene expression profiles (GEP) of the cells in different drugs were generated in triplicate at three different timepoints (6, 12, 24 hours) and the GEP of the cells in DMSO treated was eight times at the same timepoints. In addition, the drug--response curve from single agent treatment of OCI-Ly3 is also given. The challenge is to use the provided data to predict the order of efficacy of 91 pairs of drug combinations from the most synergistic to the most antagonistic.](psp40004-00e9-f1){#fig01}

In this study we hypothesize that these changes in gene expression after exposure of a drug can be used to predict these drug interaction effects. In particular, two drugs having significantly differentiated gene expression changes, where a number of specific genes in the same direction (up or down) will have a synergistic effect. The more specific genes affected in the same direction will be directly correlated to a higher synergistic effect. Conversely, the more specific genes affected in opposite directions will be directly correlated to a higher antagonistic effect. Our research attempts to infer the synergistic or antagonistic effect from two drugs based on the above biological assumption. A novel drug interaction scoring algorithm was then developed. There are some factors that remain unknown in influencing the prediction performance for the drugs interaction. One factor is the optimal drug exposure time for the drug responsive gene expression measurement; and the other factor is the core gene set selection, which include genes that are responsible for drug interaction prediction. In this work these two problems were extensively investigated using the dose--responsive curves and the gene expression data of the single drug response from the OCI-LY3 DLBCL cell line of DREAM7-4-2. Finally, the performance of our drug interaction score and its biological assumption was evaluated in five published GEO databases from six drug interaction studies.

RESULTS
=======

Overview
--------

Our method hypothesizes that a single drug effect on the OCI-LY3 cell can be attributed to the expression change from a particular set of genes, i.e., core genes set. The synergistic/antagonistic effects between a pair of drugs was derived and predicted from this core genes set. **Figure** [2](#fig02){ref-type="fig"} shows the whole drug interaction prediction process in detail. It has three parts: (i) the drug interaction scoring and prediction in the core genes set (left side of **Figure** [2](#fig02){ref-type="fig"}); (ii) the drug interaction calculation from the observed dose response curve (right side of **Figure** [2](#fig02){ref-type="fig"}); (iii) the probabilistic concordance (PC) index calculation between the experimental drug interaction ranking and the predicted drug interaction ranking (the bottom of **Figure** [2](#fig02){ref-type="fig"}). The drug interaction prediction algorithm is the essential part of the study. It includes seven steps (left side of **Figure** [2](#fig02){ref-type="fig"}): (1) Input data is prepared, including the gene expression profiles of all samples in different drug treatment groups and the DMSO control group; (2) quality control analysis is conducted. It uses principle components analysis (PCA) to identify and remove outlier samples; (3) differential expression genes are identified between drug treatment and DMSO through ANOVA method; (4) core genes set is selected (see **Figure** [3](#fig03){ref-type="fig"}), including the whole genes set, the drug sensitive genes set, the drug sensitive minus drug nonsensitive genes set, and the known drug target genes set; (5) calculate the drug interaction score; (6) store the prediction result for each drug pair; (7) the scoring algorithm comprises all drug pairs, and all the predicted drug interactions were ranked from the most synergistic to the most antagonistic. The drug interaction calculation from the observed dose response curve (right side of **Figure** [2](#fig02){ref-type="fig"}), includes three steps: (a) Calculate the expected fractional inhibition f*~xy~* from two individual drugs\' IC~20~; (b) measure the *f~AB~* from the cell treated with two drugs together; (c) calculate and rank the drug interaction index, excess over bliss(*eob*), from *f~xy~* and *f~AB~*, collectively.

![Schematics of data processing. The data processing flow included three parts: (1) The drug interaction scoring by its gene expression on the left; (2) the drug interaction observation by calculation of single drug response curve, which is shown on the right; (3) the calculation of the PC index of which the comparison between the scoring prediction and the result of the observed experiment, which is shown on the bottom.](psp40004-00e9-f2){#fig02}

![Core gene selection is used to determine the effectiveness of synergism for all the 91 possible two drug combinations. (a) All possible gene probes are used. (b) The gene set is determined by selecting all the sensitive probes from the union of all five low IC~20~ drugs. (c) The third set is determined by subtracting the union of all nonsensitive differentially expressed gene probes from the four high IC~20~ drugs. (d) The fourth scheme only selects the drug targeted gene probes reported in MetaDrug database. (e) The genes set of a--d will take part in the drug interaction score respectively to test the reliability of the drug combination.](psp40004-00e9-f3){#fig03}

Data preprocessing
------------------

PCA is conducted first for the quality control of gene expression data. PCA achieves the dimensionality reduction by finding new axes, i.e., principal components (PCs), where top PCs can account for the majority of variance in the data.[@b20] In general, PC~1~ and PC~2~ represent the highest of the variance in data among all the PCs; here they are routinely used to express the main intrinsic factor of samples variance. **Supplementary [Figure 1](#sd1){ref-type="supplementary-material"}** shows the preprocessing result of gene expression by using PCA for outliers\' recognition. It can be seen that there were two outlier samples from the drug-treated groups: mitomycin C (denoted as TH001_AP_100427_01C_E02 in experience) and H-7 (dihydrochloride, denoted as TH001_AP_100427_01C_H09 in experience). They were far away from all the other samples, hence they were removed from the follow-up analysis. Therefore, drug-treated groups of mitomycin and dihydrochloride have only two replicates, while the other drugs have three.

Core gene selection is an essential part of our drug interaction algorithm development. When the cell is treated with different compounds, their impact on cell growth will be channeled through a set of genes. This gene set is so called the core gene set. In this study, four different sets of core genes are proposed (see description in Methods and **Figure** [3](#fig03){ref-type="fig"}). The first set includes every probe set in the Affymetrix array (). The second core gene set includes all of the drug-sensitive gene probes from five drugs (aclacinomycin A, camptothecin, doxorubicin hydrochloride, geldanamycin, and trichostatin A) with low IC~20~ (the core genes number= 12500, 9000, 9862 for 6, 12, and 24 hours, respectively). The third core gene set is the drug-sensitive gene probes from five drugs of low IC~20~ minus the nonsensitive gene probes, where the nonsensitive gene probes are from the other four drugs (etoposide, H-7 dihydrochloride, mitomycin C, and rapamycin) with high IC~20~ (the core genes number= 2567, 4004, 3204 for 6, 12, and 24 hours, respectively). The fourth core gene set is derived from the drug targets reported in MetaDrug (= 80).[@b21]

Time-dependent analysis of the drug interaction prediction based on four different sets of core genes
-----------------------------------------------------------------------------------------------------

The drug interaction scores are calculated at three different timepoints after the drug treatment, 6, 12, and 24 hours for all 91 drug combinations in 14 compounds. The ranked scores are compared to observed interaction scores (i.e., *eob*) through the normalized PC index. A higher PC index represents a better concordance between the observed drug interaction and the predicted drug interaction. The highest score is 0.90 here, not 1.00, because of the noise of the experimental data. **Figure** [4](#fig04){ref-type="fig"} shows the comparison result of the drug interaction prediction in four sets of core genes at 6, 12, and 24 hours. It can be observed that the gene expression after a 12-hour drug treatment had a better performance than the 6- and 24-hour timepoints because of its high PC index in four different probes set, and the PC index reaches the largest value of 0.605. In addition, the performance of the sensitive probes is better than the other three core gene selections at 12 hours.

![Comparison result of the drug interaction prediction for four sets of core genes at different times. The y-axis is the probabilistic concordance-index (PC index) and shows that the concordance between the predictions result and the gold standard at 6, 12, and 24 hours.](psp40004-00e9-f4){#fig04}

Gene expression based probe selection vs. known drug target-based probe selection
---------------------------------------------------------------------------------

These two core gene selection schemes are based on two totally different assumptions. Gene expression-based probe selection is a purely discovery-based approach, whereas drug target-based probe selection is a candidate target approach. It focuses on the known protein targets of the drugs from the MetaDrug database.[@b21],[@b22] According to our time-dependent analysis of drug interaction prediction between these two core genes set selection schemes, the gene expression based on the drug-sensitive core gene set outperformed the target gene core set at any timepoint of 6, 12, and 24 hours. After 12 hours of drug treatment, the PC index of the drug sensitivity core set has a PC index of 0.605, while the drug target score has a PC index of 0.540 (**Figure** [4](#fig04){ref-type="fig"}). These results confirm our hypothesis that the discovery-oriented and less biased drug sensitive core gene set outperforms the knowledge-driven and potentially biased drug target core gene set for DDI prediction.

Drug interaction prediction
---------------------------

Using the drug sensitivity core gene set after 12 hours drug treatment, a score was calculated for each drug pair. Ranks are assigned to drug pairs using these scores. The final scores range from +24.06% (most synergistic) to --2.33% (most antagonistic). Whenever drug combinations had the same score, a higher ranking is given to the drug pair that has a greater number of total genes affected by the two drugs. **Table** [1](#tbl1){ref-type="table"} is a list of drug combinations with their ranks in terms of synergism. The most synergistic pair has the highest rank. The pair with the most antagonistic effect has the lowest rank. Each pair that results in lower ranking than the trichostatin A & vincristine combination has a positive score and will have a synergistic effect *in silico*. All pairs that result in scores higher than the trichostatin A & vincristine pair will have an antagonistic effect *in silico*.

###### 

Ranking of pairwise drug combinations based on the gene expression profiling scoring, discussed in the Methods

  Drug combination                              Rank                           Observed ranking (gold standard)
  --------------------------------------------- ------------------------------ ----------------------------------
  Camptothecin & H-7                            1                              10
  Camptothecin & Trichostatin A                 2                              56
  Cycloheximide & H-7                           3                              9
  Cycloheximide & Rapamycin                     4                              78
  Geldanamycin & Rapamycin                      5                              47
  Camptothecin & Doxorubicin                    6                              16
  Camptothecin & Etoposide                      7                              15
  Cycloheximide & Trichostatin A                8                              37
  Doxorubicin & Etoposide                       9                              24
  Monastrol & Rapamycin                         10                             48
  Camptothecin & Methotrexate                   11                             62
  Monastrol & Trichostatin A                    12                             18
  Camptothecin & Mitomycin C                    13                             5
  H-7 & Trichostatin A                          14                             19
  Rapamycin & Trichostatin A                    15                             60
  Geldanamycin & H-7                            16                             31
  Camptothecin & Cycloheximide                  17                             59
  Doxorubicin & Mitomycin C                     18                             4
  Etoposide & Mitomycin C                       19                             3
  Etoposide & Trichostatin A                    20                             11
  H-7 & Rapamycin                               21                             27
  Cycloheximide & Monastrol                     22                             12
  Etoposide & Rapamycin                         23                             83
  Doxorubicin & Trichostatin A                  24                             8
  Cycloheximide & Etoposide                     25                             69
  Doxorubicin & Rapamycin                       26                             87
  Blebbistatin & Rapamycin                      27                             57
  Camptothecin & Monastrol                      28                             67
  Blebbistatin & H-7                            29                             7
  Methotrexate & Trichostatin A                 30                             55
  Geldanamycin & Trichostatin A                 31                             58
  Etoposide & Methotrexate                      32                             76
  Geldanamycin & Monastrol                      33                             75
  Doxorubicin & H-7                             34                             1
  Etoposide & H-7                               35                             6
  Mitomycin C & Trichostatin A                  36                             13
  Aclacinomycin A & H-7                         37                             26
  Etoposide & Monastrol                         38                             90
  Geldanamycin & Vincristine                    39                             29
  Blebbistatin & Cycloheximide                  40                             85
  Cycloheximide & Mitomycin C                   41                             17
  Methotrexate & Mitomycin C                    42                             28
  H-7 & Mitomycin C                             43                             2
  H-7 & Monastrol                               44                             14
  Aclacinomycin A & Geldanamycin                45                             61
  Cycloheximide & Methotrexate                  46                             64
  H-7 & Vincristine                             47                             43
  Blebbistatin & Monastrol                      48                             21
  Aclacinomycin A & Vincristine                 49                             49
  Rapamycin & Vincristine                       50                             42
  Methotrexate & Monastrol                      51                             35
  Aclacinomycin A & Rapamycin                   52                             65
  Blebbistatin & Doxorubicin                    53                             72
  Doxorubicin & Methotrexate                    54                             73
  Cycloheximide & Doxorubicin                   55                             68
  Doxorubicin & Monastrol                       56                             91
  Cycloheximide & Geldanamycin                  57                             81
  Cycloheximide & Vincristine                   58                             38
  Aclacinomycin A & Doxorubicin                 59                             53
  Blebbistatin & Geldanamycin                   60                             39
  Doxorubicin & Geldanamycin                    61                             46
  Blebbistatin & Camptothecin                   62                             88
  Blebbistatin & Trichostatin A                 63                             80
  Blebbistatin & Methotrexate                   64                             52
  Aclacinomycin A & Blebbistatin                65                             74
  Blebbistatin & Vincristine                    66                             30
  Mitomycin C & Rapamycin                       67                             66
  Blebbistatin & Mitomycin C                    68                             34
  Aclacinomycin A & Camptothecin                69                             86
  Monastrol & Vincristine                       70                             20
  Mitomycin C & Monastrol                       71                             82
  Trichostatin A & Vincristine                  72                             50
  Blebbistatin & Etoposide                      73                             79
  Aclacinomycin A & Mitomycin C                 74                             22
  Doxorubicin & Vincristine                     75                             41
  Methotrexate & Vincristine                    76                             25
  Aclacinomycin A & Methotrexate                77                             77
  Mitomycin C & Vincristine                     78                             70
  Aclacinomycin A & Etoposide                   79                             45
  Aclacinomycin A & Monastrol                   80                             23
  Aclacinomycin A & Cycloheximide               81                             33
  Etoposide & Vincristine                       82                             32
  Geldanamycin & Mitomycin C                    83                             63
  Camptothecin & Vincristine                    84                             51
  Etoposide & Geldanamycin                      85                             44
  Aclacinomycin A & Trichostatin A              86                             84
  Methotrexate & Rapamycin                      87                             40
  Geldanamycin & Methotrexate                   88                             54
  H-7 & Methotrexate                            89                             36
  Camptothecin & Geldanamycin                   90                             71
  Camptothecin & Rapamycin                      91                             89
  Compound pair with additive activity (IC36)   Trichostatin A & Vincristine   

Ranking is from most synergistic to most antagonistic. Trichostatin A & vincristine showed a purely additive effect.

Drug interaction scoring algorithm validation using GEO datasets
----------------------------------------------------------------

Six drug interactions were reported in five published GEO datasets (**Supplementary File 2**). Both the single drug responsive gene expression profiles and their combinatory effect gene expression profiles are available. In order to verify the sensitive genes set of a single drug, the main factor for the synergistic or the antagonistic contribution is the combination drug efficacy. The consistency of differentially expressed genes is compared between a single drug and combinatory drug treatment. Our score algorithm in **Figure** [5](#fig05){ref-type="fig"} assumes that the combinatory effect of two drugs is more consistent with the concordance between two single drug effects if they are synergistic than they are not. In **Table** [2](#tbl2){ref-type="table"}, it can be seen that among six drug pairs three drug pairs have an additive effect, and the other three pairs have a synergy effect. Column (A) of **Table** [2](#tbl2){ref-type="table"} displays the number of differentially expressed genes by the combinatory effect of two drugs. Column (B) shows how many genes in column (A) had the same directional differential expression from both the single drug treatments, which is the primary assumption in our algorithm (**Figure** [5](#fig05){ref-type="fig"}). Column (C) presents the ratio of (B) over (A), i.e., a concordance ratio. It is interesting to see that the additive drug pairs have a concordance rate (0.46, 0.34, 0.50), while the synergistic drug pairs have a higher concordance rate (0.51, 0.54, 0.73). These results support that the synergistic drug interaction has a stronger concordance rate than the additive drug interaction.

###### 

Concordance between drug combinatory effect in experiment and the concordance ratio

  Data sets   Cancer type                 Drug combination                          Drug interaction affection in biology experience                                    Differential expressed genes by the combinatory effect of two drugs (A)   The genes number of the same variation direction (B)   Concordance ratio (C)
  ----------- --------------------------- ----------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------ -----------------------
  GSE45587    Neuroblastoma               All-trans retinoic acid & valproic acid   The treatment of valproic acid is augmented by all-trans retinoic acid (Additive)   6965                                                                      3212                                                   0.46
  GSE11550    Melanoma                    Elesclomol & paclitaxel                   Drug combination has significant effect in cancer (Additive)                        5578                                                                      1903                                                   0.34
  GSE43452    Glioblastoma                Temozolomide & Y.15 (FAK inhibitor)       Combination can significantly reduce tumor growth (Additive)                        6479                                                                      3249                                                   0.50
  GSE33366    Breast cancer               Tamoxifen & BMS754807                     Synergy                                                                             5191                                                                      2664                                                   0.51
  GSE33366    Breast cancer               Letrozole & BMS754807                     Synergy                                                                             3440                                                                      1843                                                   0.54
  GSE6914     Nonsmall cell lung cancer   Bexarotene & gemcitabine                  Resensitized (Sysnergy)                                                             4587                                                                      3368                                                   0.73

![The scoring scheme of the drug combination effect based on analyzing gene expression data. The score formula and a specific calculation processing of Drug A and Drug B at high IC~20~ in 24 hours is given.](psp40004-00e9-f5){#fig05}

DISCUSSION
==========

Multidrug combinations are thought to attack drug resistance in cancer. By utilizing treatments involving more than one drug, it is thought that one drug will kill the cells resistant to the other drug and the other drug will kill the cells resistant to the first drug; thereby, the combination drugs treatment prevents the regrowth of the disease with resistance to the current therapy.[@b9],[@b23] This method has been very popular for fighting cancer.[@b24] However, testing all possible combination *in vitro* in cancer is not feasible due to the large combinatorial search space. DREAM7-4 provided a platform to develop models that predict the synergistic/antagonistic activity of drug pairs in the OCI-LY3 cell line.[@b19] We are one of 31 contestants for the DREAM7-4 challenge. In this work, based on the gene expression profile of before and after treatment of a single drug and its dose--responsive curve, a novel drug interaction scoring algorithm was developed to predict the synergistic or the antagonistic effects of two drug combinations in cancer. Fourteen drugs and their combinatory experiments in a DLBCL cancer cell were investigated. The drugs\' interaction effect was scored by counting the differentially expressed genes in the core gene set that went in either the same or the opposite direction between two drug treatments under their IC~20~s. The prediction scores were compared with the observed drug interaction data at 6, 12, and 24 hours with a PC index. The test result shows that the drug-sensitive gene set can achieve the best prediction result and its PC index equals 0.605, which was extremely close to the best prediction PC index = 0.613 in the DREAM7-4-2 challenge. In addition, using only the known drug targets cannot provide comparable drug interaction prediction performance, as the core gene sets do, which were drug-responsive genes selected from whole genome differential expressed genes. Finally, our score schema is validated by using drug interaction data collected from the GEO. Using the additional gene expression data after the combined two exposures, we found that differentially expressed genes in the synergistic drug interaction pairs had higher concordance rates than those of additive drug interaction pairs. This study provides a valuable drug-combinatory effect predictive model that can screen synergistic drug interaction pairs from single drugs\' gene expression profiles.

Our current best drug interaction performance, a PC index of 0.605, is still far from the optimal prediction, 0.90. There are strategies that will likely improve the drug interaction prediction. First, our current best core gene set, drug-sensitive genes, are only based on five sensitive drugs. We believe more sensitive drugs and their responsive genes will help to improve the prediction. Second, our current drug interaction prediction algorithm is not a truly supervised method; it is based on a biological assumption of concordantly differentially expressed genes between single drugs and their combinations. We still expect to design a more proper supervised machine learning algorithm combining our method to gain better performance in the future. Third, the current scoring scheme is a highly simplified method, which does not differentiate or weight the highly or lowly expressed genes. It is worthwhile to investigate the drug interaction prediction performance with more sophisticated methods. Finally, a drug interaction net provides us a new view to obtain drug combination efficiency by integrating molecular, therapy, and pharmacological data.[@b4],[@b23],[@b25] Based on a drug network and multiple data merging technology, looking for the core genes set by drug-targeted and disclosing the rule between the drugs and the genes from DDIs will provide us much clinic direction for cancer treatment in the future, as will also be our goal in the next study.

METHODS
=======

Cell culture, drug treatment, and gene expression profiling
-----------------------------------------------------------

The diffuse large B-cell lymphoma (DLBCL) cell line was obtained from the University Health Network (Toronto, Canada) and was cultured under standard conditions (37°C in humidified atmosphere, with 5% CO~2~) in Iscove\'s modified Dulbecco\'s medium (IMDM) supplemented with 10% fetal calf serum (FCS). Each drug was titrated in the OCI-LY3 cell line in a 20-point titration curve. Cell viability following drug treatment was determined using the CellTiter-Glo (Promega, Madison, WI). An IC~20~ value for each drug was calculated using Dose Response Fit and Calculate EC*x* (epirubicin, cisplatin, and Xeloda) components from the Pipeline Pilot Plate Data Analytics collection. For drugs for which more than 20% viability reduction could not be reached, a default concentration of 100 μM was used. For generation of gene expression profiles, the OCI-LY3 cells were seeded in tissue culture-treated 96-well plates at a density of 50,000 cells per well (100 μL) and treated at the IC~20~ concentrations of each of the drugs at 24 and 48 hours. In the assay, three timepoints (6, 12, and 24 hours) were analyzed for gene expression profiling. All profiles were generated in triplicate biological replicates except DMSO-treated samples, which were hybridized in octuplicate since they were used as internal controls for each timepoint. To confirm viability data at each step, identical plates were produced and cell viability assessed using the CellTiter-Glo reagent (Promega). Total RNA was isolated with the Janus automated liquid handling system (Perkin Elmer, Boston, MA) using the RNAqueous-96 Automated Kit (Ambion, Austin, TX), quantified by a NanoDrop 6000 spectrophotometer and quality checked with an Agilent Bioanalyzer. 300 ng of each of the samples with RIN value \>7 were converted to biotinylated cRNA with the Illumina TotalPrep-96 RNA Amplification Kit (Ambion) using a standard T7-based amplification protocol and hybridized on the Human Genome U219 96-Array Plate (Affymetrix, Santa Clara, CA). Hybridization, washing, staining, and scanning of the array plates were performed on the GeneTitan instrument (Affymetrix) according to the manufacturer\'s protocols. The drugs for which IC~20~ values were reported includes aclacinomycin A, camptothecin, doxorubicin hydrochahloride, geldanamycin, trichostatin A, etoposide, H-7 dihydrochloride, mitomycin C, and rapamycin. For blebbistatin, cycloheximide, methotrexate, monastrol, and vincristine, IC~20~ values were not reported. All of the detailed information has been provided by the DREAM project.[@b18],[@b19]

Experimental determination of synergy
-------------------------------------

For each drug, IC~20~ was determined (as described above) at 60 hours following drug treatment by measuring cell viability and generating a dose--response curve. Each drug combination was then tested at the respective IC~20~ (or 100 μM) concentration of the individual drugs in five replicates. All drugs and combinations are diluted in DMSO, with a final DMSO concentration of 0.4%. Cells were placed at a density of 2,000 cells per well in 384-well plates and drugs were added at 12-hour intervals after seeding by drug transfers of serially diluted drugs. Assay plates were then incubated for 60 hours followed by addition of 25 μL of CellTiter-Glo (Promega) at room temperature. Plates were read on Envision (Perkin Elmer) using an enhanced luminescence protocol.

Data available for drug interaction prediction and validation
-------------------------------------------------------------

The experimental data were generated by the NCI-nominated lab, and each competition team receives the data and conducts the computation. The single drug treated and untreated gene expression data at 6, 12, and 24 hours were used. Only 9 out of 14 drug dose-responsive curves are used for developing the drug combinatory synergy predictive model. Among these nine drugs, five drugs are highly sensitive (IC~20~ \<1 μM), and the other four are not sensitive (IC~20~ \>10 μM). The predictive performance is then compared to the observed drug interaction data measured by the Excess over Bliss (called *eob*, see the following description).

Gene expression-based drug combinational effect model
-----------------------------------------------------

### Drug-induced differential gene expression

All gene expression samples were normalized with the Robust Multichip Averaging (RMA) normalization method using the Bioconductor package in R.[@b26] At each timepoint of drug treatment, differential gene expression analysis was conducted between treated samples and DMSO samples. The analysis of variance method (ANOVA) was used to analyze the differences between group means and their associated procedures (such as \"variation\" among and between groups). It is useful in comparing (testing) two or more means (groups or variables) for statistical significance. Here the differentially expressed gene probe selection was selected by ANOVA statistical analyses between DMSO and drug treatment samples (using the ANOVA function in R), with *P* \< 0.05 regarded as the significant threshold.

### Core gene set selection

To test our hypothesis correction, four schemes of core gene set selection were selected (**Figure** [3](#fig03){ref-type="fig"}). Differentially expressed genes for all drugs were identified by comparing their drug treatment samples with control (DMSO) samples. All differentially expressed gene probe with a significant *P* value (*P* ≤ 0.05) were combined in each IC~20~ at 24 hours after drug treatment. The first scheme simply selects all the probes (**Figure** [3](#fig03){ref-type="fig"}**a**). The second scheme selects only the sensitive probes derived from the union of all the differentially expressed gene probes from five low IC~20~ drugs (**Figure** [3](#fig03){ref-type="fig"}**b**). The third scheme selects the sensitive probes to five low IC~20~ drugs, but not the nonsensitive probes. The nonsensitive probes are derived from the union of all the differentially expressed gene probes from the four high IC~20~ drugs (**Figure** [3](#fig03){ref-type="fig"}**c**). The second and third schemes are used in determining which probes can be kept as different sets used in determining synergism. The fourth scheme only selected the drug targeted gene probes reported in MetaDrug (**Figure** [3](#fig03){ref-type="fig"}**d**). The drug targets are reported in **Supplementary Table 1**.

The drug interaction score is constructed based on a scoring scheme presented in **Figure** [5](#fig05){ref-type="fig"}. The denominator of the score is the number of core gene probes. The core gene selection follows the previous point. Then the synergy score between two drugs is the number of gene probes that are consistently up- or downregulated (i.e., showing the same direction of gene expression change) after the drug treatment. The antagonism score is calculated as the number of the genes showing the reversed regulation direction. The drug interaction score is the synergistic score minus the antagonism score normalized by the number of core gene probes. In **Figure** [5](#fig05){ref-type="fig"}, a specific calculated example for the score of Drug A and Drug B is shown in IC~20~ 24 hours. The probe changing direction in Drug A or Drug B is decided by the ANOVA statistical analyses result between the DMSO group and the drug treatment group.

Excess over Bliss as a measurement for synergy
----------------------------------------------

The Bliss additivism (or Bliss independence) model[@b27] predicts that if the *i*-th pair drug and, with experimentally measured fractional inhibitions and, have an additive effect, then the expected fractional inhibition,, induced by their combination should be: Here the IC is 20%,,. Excess over Bliss is determined by computing the difference in fractional inhibition induced by its observed value of Drug A and Drug B combination and expected fractional inhibition is a ratio with the observed cell viability after drug combination treatment in time 60 hours to the ones of before single drug treatment plus. When the drug pair for, it has an additive behavior, whereas the drug pair with positive (or negative) values has synergistic (or antagonistic) behavior. In fact, here the propagation of errors using the standard error mean of fractional inhibitions is used to compute the standard error of the mean.

Scoring using probabilistic concordance index
---------------------------------------------

In order to calculate the concordance between predicted and observed ranks of drug-pairs, a concordance index (*c-index*) is designed to compute the proportion of concordance between them to quantify the quality of ranking of all predictions. To compute the *c-index*, we first rank the observed drug pairs and the predicted drug pairs from most synergistic to most antagonistic for each of the possible pairwise combinations. A score is computed as follows: and define the concordance index as Where *m* is the number of drug pairs, in DREAM7-4-2 problem, 14 drugs have *m* = 91 pairs. Quantification using the *c-index* assumes that there is no ambiguity in the observed rankings, and therefore both the prize and penalty for concordance and discordance is extreme. The above design method is for a specific discrete event. When it becomes a continual description in large events, the concordance index expectation can be expressed by the following formula; we called it the probabilistic concordance*-index* (*PC-index*) to measure the concordance between the observed and the predicted in large events. where *erf*\' is an error function defined as *eob* is excess over Bliss, *sem* is the standard error of the mean excess over Bliss. The probabilistic concordance (PC) index is thus defined as: For a specific event, when the predicted and the observed list of drug pairs are entirely concordant, the *c-index* can reach a maximum score of 1. But due to noise in the large data, the *PC-index* is less than 1, even for the average experimentally measured *eob in practice*. In our study, all of the challenge results and other test results find that the maximum *PC−index* (*PC*~max~) is 0.90. The minimum *PC−index* (*PC*~min~) corresponds to a prediction with exactly the opposite order compared to the average experimentally measured *eob*. Note that *PC*~min~=1−*PC*~max~. Hence, the normalized *PC−index* is defined as:

Drug interaction data from GEO
------------------------------

We identified five datasets from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). Their accession numbers are GSE45587, GSE11550, GSE43452, GSE33366, and GSE6914. These five datasets contain six drug interaction pairs (Supplement DataGEO.doc).
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Supplemental information includes two programming codes of the key modeling, five dataset and 12 result files, and detailed information can be found in the supplemental description files.

Acronyms
========

  Abbreviation   Definition
  -------------- --------------------------------------------------------
  CASP           critical assessment of structure prediction
  c-index        concordance index
  DDI            drug--drug interaction
  DLBCL          diffuse large B-cell lymphoma
  DMSO           dimethyl sulfoxide
  DREAM          dialogue on reverse engineering assessment and methods
  ECx            epirubicin, cisplatin and xeloda
  eob            excess over bliss
  FCS            fetal calf serum
  IC             inhibitory concentration
  IMDM           Iscove\'s modified Dulbecco\'s medium
  PC-index       probability concordance index
  PCs            principal components
  PCA            principal component analysis
  RMA            robust multichip averaging

Study Highlights
================

WHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC?
--------------------------------------------

1.  ✓ It is known that many cancers develop resistance to treatment involving one drug alone. Drug combination therapy can actually become synergistic in their killing power, resulting in a smaller amount of drugs needed for successful treatment.

WHAT QUESTION DID THIS STUDY ADDRESS?
-------------------------------------

1.  ✓ What is the best way to predict drug interaction on a specific cell line? Using gene expression data before and after treatment of individual drugs and their IC~20~ values, it is possible to predict the synergistic power of drug--drug combinations with relatively high accuracy.

WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
-------------------------------------

1.  ✓ Gene expression data seems to be one of the most important features in predicting DDI. Our core gene selection and gene expression-based synergy score performs well in predicting the drug combinatory synergy.

HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS
------------------------------------------------------------

1.  ✓ The development of treatments for individuals can be made more effective by utilizing the gene expression data of biopsies of the patient\'s tumor response shortly after individual drug exposures.
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Additional supporting information may be found in the online version of this article.
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